Fig. 5
From: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
Stratification analysis in subgroups of age, sex, cancer type, TMB status and drug class in the validation cohort. Breast cancer, colorectal cancer, esophagogastric cancer, glioma, head and neck cancer, renal cell carcinoma and cancer of unknown primary were combined into ‘other cancers’ as the TET1-MUT cases or deaths were insufficient for hazard ratio calculation in each single cancer type. ‘Monotherapy’ indicated monotherapy of CTLA-4, PD-1 or PD-L1 antibody; ‘combination therapy’ indicated combination therapy of CTLA-4 with PD-(L)1 antibodies